CN101912406A - 新脑苷脂用于制备治疗炎症性肠炎药物的用途 - Google Patents
新脑苷脂用于制备治疗炎症性肠炎药物的用途 Download PDFInfo
- Publication number
- CN101912406A CN101912406A CN201010188404XA CN201010188404A CN101912406A CN 101912406 A CN101912406 A CN 101912406A CN 201010188404X A CN201010188404X A CN 201010188404XA CN 201010188404 A CN201010188404 A CN 201010188404A CN 101912406 A CN101912406 A CN 101912406A
- Authority
- CN
- China
- Prior art keywords
- fusaruside
- tnbs
- mice
- intestinal
- colitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000004232 Enteritis Diseases 0.000 title claims abstract description 13
- 230000002757 inflammatory effect Effects 0.000 title claims abstract description 10
- 239000003814 drug Substances 0.000 title claims abstract description 9
- 230000000968 intestinal effect Effects 0.000 claims abstract description 11
- 208000011231 Crohn disease Diseases 0.000 claims abstract description 7
- 206010061218 Inflammation Diseases 0.000 claims abstract description 7
- 230000004054 inflammatory process Effects 0.000 claims abstract description 7
- 208000025865 Ulcer Diseases 0.000 claims abstract description 6
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 abstract description 20
- 241001149959 Fusarium sp. Species 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 238000000855 fermentation Methods 0.000 abstract description 3
- 230000004151 fermentation Effects 0.000 abstract description 3
- 239000007787 solid Substances 0.000 abstract description 3
- 208000028774 intestinal disease Diseases 0.000 abstract 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 25
- 230000001939 inductive effect Effects 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 210000001072 colon Anatomy 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 230000036285 pathological change Effects 0.000 description 6
- 231100000915 pathological change Toxicity 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
- 229960003957 dexamethasone Drugs 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 240000008289 Quercus suber Species 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 238000001061 Dunnett's test Methods 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000006727 cell loss Effects 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 210000002175 goblet cell Anatomy 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 235000016977 Quercus suber Nutrition 0.000 description 2
- 241001480064 Quercus variabilis Species 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 102100033220 Xanthine oxidase Human genes 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229930183167 cerebroside Natural products 0.000 description 2
- 229940084954 dexamethasone 1 mg Drugs 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
- 150000001784 cerebrosides Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于制药技术领域。本发明所述，从植物内生菌栓皮栎镰刀属真菌Fusarium sp.IFB-121固体发酵产物中分离得到fusaruside。Fusaruside能显著改善TNBS诱导的结肠炎。由此可见，fusaruside能明显改善免疫性肠部炎症。综上所述，fusaruside作为一种新型炎症肠病治疗药物，具有良好的抑制炎症和保护肠组织等活性，可用于各种溃疡性肠炎、克罗恩氏病及其他肠组织相关疾病的治疗并制备相应的治疗药物。
Description
一、技术领域
本发明属于制药技术领域，具体涉及一种Fusaruside用于制备治疗炎症性肠炎药物的用途。
二、背景技术
新脑苷脂Fusaruside最初是从菌种Fusarium sp.IFB-121中提取得到(Shu，R.G.，et al.2004.Antibacterial and xanthine oxidase inhibitory cerebrosides fromFusarium sp IFB-121，an endophytie fungus in Quercus variabilis.Lipids.39(7)：p.667-673.)，它的化学结构自被报道以来，对该化合物的研究甚少，关于其药理活性方面，尤其是抑制炎症反应、保护消化道器官的作用等，迄今未见报道。本发明主要发现了fusaruside对2，4，6-三硝基苯磺酸(TNBS)诱导的炎症性肠炎具有显著的改善作用。该肠炎模型被公认为克罗恩氏病及溃疡性结肠炎的动物模型之一。
三、发明内容
本发明的目的是提供fusaruside的一种新用途。
本发明所说的fusaruside的新用途是：Fusaruside用于制备治疗炎症性肠炎药物的用途。所说的炎症性肠炎包括各种溃疡性肠炎、克罗恩氏病及其它肠组织相关疾病。
本发明所说的fusaruside可通过下述方法获得：从植物内生菌栓皮栎镰刀属真菌Fusarium sp.IFB-121固体发酵产物中分离得到fusaruside。即提取Fusariumsp.IFB-121菌液，胶柱层析，ODS反相柱层析，20％甲醇/水系统——纯甲醇洗脱，最后用HPLC制备得fusaruside。
本发明的药理实验表明：对TNBS诱导的结肠炎的小鼠，2.5、5、10mg/kg的fusaruside均能提高其生存率。5和10mg/kg的fusaruside可显著减轻TNBS诱导的结肠炎小鼠体重的降低。对TNBS诱导的结肠炎的小鼠，5和10mg/kg的fusaruside可显著改善肠部红斑，出血，水肿，血便，腹泻，束紧形成，出现粘液等病变。对TNBS诱导的结肠炎的小鼠，5和10mg/kg的fusaruside可显著改善上皮腺体层增厚，溃疡，隐窝缺失，溃疡处大量中性粒细胞等病变。
以上显示，fusaruside能显著改善TNBS诱导的结肠炎，显示出良好的抑制炎症的作用。已知TNBS诱导的小鼠结肠炎是炎症性肠炎及克罗恩氏病的典型动物模型，故其作为克罗恩氏病、溃疡性结肠炎及其它肠组织炎症相关疾病的治疗药物中得到应用。
四、附图说明
图1Fusaruside对TNBS诱导的结肠炎小鼠体重的影响。
C57BL/6小鼠随机分成6组，分别为正常组，TNBS组，fusaruside 2.5、5、10mg/kg和dexamethasone，造模后连续经腹腔给药三天，每天称量体重。体重结果以平均数±标准误表示。*：P＜0.05vs模型组小鼠；**：P＜0.01vs模型组小鼠(Dunnett’s test)。
图2Fusaruside对TNBS诱导的结肠炎小鼠的结肠宏观指标分析。
第三天，取TNBS诱导的结肠炎小鼠的结肠，进行宏观指标评分。结果以平均数±标准误表示。*：P＜0.05vs TNBS组小鼠；**：P＜0.01vs TNBS组小鼠(Dunnett’s test)。
图3Fusaruside对TNBS诱导的结肠炎小鼠的结肠病理切片微观指标分析。
第三天，取TNBS诱导的结肠炎小鼠的结肠，并切取相同位置的结肠组织，石蜡包埋，用H&E染色，并进行微观学评分，结果以平均数±标准误表示。*：P＜0.05vs TNBS组小鼠；**：P＜0.01vs TNBS组小鼠(Dunnett’s test)。
五、具体实施方式
本文所涉及的栓皮栎镰刀属真菌Fusarium sp.IFB-121是从栓皮栎的树皮中提取(Shu，R.G.，et al.2004.Antibacterial and xanthine oxidase inhibitorycerebrosides from Fusarium sp IFB-121，an endophytic fungus in Quercus variabilis.Lipids.39(7)：p.667-673.)，由南京大学谭仁祥教授提供。
实施例一Fusaruside的提取分离及结构
本发明所研究的fusaruside系从植物内生菌栓皮栎镰刀属真菌Fusarium sp. IFB-121固体发酵产物中分离得到。即在50L YPD(10％Yeast extract；20％Peptone；20％Dextrose)培养基中，于28℃，180rpm，培养Fusarium sp.IFB-121，7天。用纱布过滤并抽滤制菌饼，干燥，然后再用丙酮浸泡菌饼12h，每30min搅拌一次，浓缩提取液，得粗膏52g。对提取液进行硅胶柱层析，洗脱剂为1：40％丙酮的氯仿溶液及2：20％甲醇的丙酮溶液。接着用ODS反相柱层析，20％甲醇/水系统——纯甲醇洗脱。98％的甲醇/水洗脱时得到脑苷脂组分。最后用HPLC制备，洗脱条件为97％色谱甲醇(水)，得fusaruside，其结构式如下。
实施例二Fusaruside的药理实验及结果分析
1)TNBS诱导的结肠炎
取C57BL/6小鼠(8-10周)，随机分成6组，除正常组外先用150μl1％TNBS溶液涂在成年雄性C57BL/6小鼠的刮毛后的腹部。七天后，用1％的戊巴比妥麻醉小鼠后轻轻直肠注射TNBS溶液(2.5mg TNBS在50％乙醇溶液中)。其中4组在直肠注射后分别经腹腔给2.5、5、10mg/kg的fusaruside和1mg/kg的地塞米松(dexamethasone)，模型组和正常组给予等量的PBS，连续3天，动物每天测量体重，观察小鼠存活率和腹泻情况。第三天，取小鼠结肠，先进行宏观指标评分，再切取相同位置的结肠组织，石蜡包埋，用H&E染色，进行病理学评分。
2)Fusaruside对TNBS诱导的结肠炎小鼠生存率的影响
在第三天时，在模型组中还有30％的小鼠存活，2.5、5、10mg/kg的fusaruside和1mg/kg的地塞米松处理组中则分别为40％、40％、50％和40％，该结果说明 2.5、5、10mg/kg的fusaruside均能增加结肠炎小鼠的存活率。
3)Fusaruside对TNBS诱导的结肠炎小鼠体重的影响
如图1所示，在模型组小鼠体重有明显的下降。在第三天时，与模型组小鼠相比，5和10mg/kg的fusaruside，以及1mg/kg dexamethasone对结肠炎小鼠的体重下降均有显著改善作用。
4)Fusaruside对TNBS诱导的结肠炎其它宏观指标的影响
宏观学评分规则为，出现出血、水肿、束紧形成、溃疡、血便、出现粘液、腹泻各计1分，红斑和粘连根据程度可给0-2分。如图2所示，肠组织切片分析显示与正常组相比，模型组有典型的红斑，出血，水肿，血便，腹泻，束紧形成，并出现粘液。评分结果显示，fusaruside 5、10mg/kg均能显著改善这些病变，作用呈剂量依赖性。Dexamethasone 1mg/kg也能改善这些病变。
5)Fusaruside对TNBS诱导的结肠炎微观指标的影响
微观学评分规则为，无炎症计为0分，少量粒细胞的浸润计为1分，中度粒细胞的浸润计为2分，高度粒细胞的浸润，中度纤维化，高血管密度，肠壁变厚，隐窝畸变及Goblet细胞丢失计为3分，透壁浸润，大片Goblet细胞丢失，多处纤维化及隐窝大面积丢失计为4分。如图3所示，肠组织切片分析显示与正常组相比，模型组有典型的结肠炎特点如隐窝畸变，Goblet细胞丢失，单核细胞侵润和严重的粘膜损伤。相关评分结果显示，fusaruside 5、10mg/kg均能显著改善这些病变，作用呈剂量依赖性。Dexamethasone 1mg/kg也能改善这些病变。
本发明所述，fusaruside可用于制备多种克罗恩氏病和溃疡性结肠炎及其它肠组织炎症相关疾病的治疗药物。
Claims (2)
1.Fusaruside在制备治疗炎症性肠炎药物中的应用。
2.如权利要求1所说的应用，其特征在于所说的炎症性肠炎是克罗恩氏病、溃疡性肠炎或其它肠组织炎症相关疾病。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010188404XA CN101912406B (zh) | 2010-06-01 | 2010-06-01 | 新脑苷脂用于制备治疗炎症性肠炎药物的用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010188404XA CN101912406B (zh) | 2010-06-01 | 2010-06-01 | 新脑苷脂用于制备治疗炎症性肠炎药物的用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101912406A true CN101912406A (zh) | 2010-12-15 |
| CN101912406B CN101912406B (zh) | 2012-02-29 |
Family
ID=43320155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010188404XA Expired - Fee Related CN101912406B (zh) | 2010-06-01 | 2010-06-01 | 新脑苷脂用于制备治疗炎症性肠炎药物的用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101912406B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108795787A (zh) * | 2018-06-21 | 2018-11-13 | 泰山医学院 | 一种产fusaruside工程菌及其构建方法与应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080152737A1 (en) * | 2006-09-20 | 2008-06-26 | Academia Sinica | Cancer and inflammatory disorder treatment |
-
2010
- 2010-06-01 CN CN201010188404XA patent/CN101912406B/zh not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080152737A1 (en) * | 2006-09-20 | 2008-06-26 | Academia Sinica | Cancer and inflammatory disorder treatment |
Non-Patent Citations (3)
| Title |
|---|
| 《Gastroenterology》 19891231 Gerald P.Morris, et al. Hapten-induced model of chronic inflammation and ulceration in the rat colon 795-803 1-2 第96卷, 2 * |
| 《Lipids》 2004 R.G.Shu, et al. Antibacterial and xanthine oxidase inhibitory cerebrosides from Fusarium sp.IFB-121,an Endophytic fungus in Quercus variabilis 667-673 1-2 第39卷, 第7期 2 * |
| 《中国药理学通报》 199808 郑礼等 大鼠溃疡性结肠炎模型的实验研究 370-372 1-2 第14卷, 第4期 2 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108795787A (zh) * | 2018-06-21 | 2018-11-13 | 泰山医学院 | 一种产fusaruside工程菌及其构建方法与应用 |
| CN108795787B (zh) * | 2018-06-21 | 2020-07-07 | 泰山医学院 | 一种产fusaruside工程菌及其构建方法与应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101912406B (zh) | 2012-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10603344B2 (en) | Plant extract from low-THC cannabis for the treatment of disease | |
| Dong et al. | In vitro evaluation of antioxidant activities of aqueous extracts from natural and cultured mycelia of Cordyceps sinensis | |
| Taylor et al. | Antiviral activities of medicinal plants of southern Nepal | |
| Liu et al. | Anti-Helicobacter pylori activity of bioactive components isolated from Hericium erinaceus | |
| Vazirian et al. | Anti-inflammatory effect, total polysaccharide, total phenolics content and antioxidant activity of the aqueous extract of three basidiomycetes | |
| CN107648341A (zh) | 用于治疗和预防感染的植物提取物 | |
| Makinde et al. | Antidiabetic, antioxidant and antimicrobial activity of the aerial part of Tiliacora triandra | |
| JP2018510890A (ja) | インジゴ・ナチュラリス由来のエキス及びそれを調製する方法 | |
| JPH07277942A (ja) | 皮膚外用剤 | |
| KR20100007122A (ko) | 항균 또는 항진균용 조성물 | |
| CN101912406B (zh) | 新脑苷脂用于制备治疗炎症性肠炎药物的用途 | |
| KR101394550B1 (ko) | 장미의 꽃 추출물을 유효성분으로 포함하는 항균용 또는 항염증용 조성물 | |
| KR20070024147A (ko) | 리포좀으로 안정화 된 우렁쉥이 또는 멍게 외막 추출물을함유하는 피부 노화 억제 및 주름 개선 화장료 조성물 | |
| KR101986629B1 (ko) | 포도 전정가지 추출물을 유효성분으로 함유하는 항가려움용 조성물 | |
| Chaiyana et al. | Anti‐Inflammatory and Antimicrobial Activities of Fermented Ocimum sanctum Linn. Extracts against Skin and Scalp Microorganisms | |
| JP2010538058A (ja) | ビティス・ビニフェラの種抽出物の調製方法及び該抽出物を含む関節リウマチの予防または治療用の医薬組成物 | |
| Rahmayanti et al. | Ethyl acetate fraction of Garcinia mangostana Linn pericarp extract: Anti—Candida albicans and epithelial cytotoxicity | |
| KR20180059317A (ko) | 선복화 단백다당체 또는 선복화 올리고당/펩타이드 복합체를 유효성분으로 함유하는 피부 외용제 조성물 및 이의 제조방법 | |
| CN106135204A (zh) | 番石榴属植物中二苯酮类化合物作为抗真菌的应用 | |
| Tongmai et al. | Prevention potential of Cordyceps militaris aqueous extract against cyclophosphamind-induced mutagenicity and sperm abnormality in rats | |
| KR20170040659A (ko) | 고염 미생물의 발효 추출물을 포함하는 조성물 | |
| KR101645355B1 (ko) | 삼채 추출물 또는 삼채 분획물을 유효성분으로 함유하는 아토피 피부 개선용 피부 외용제 | |
| Habbu et al. | Antidiabetic potential of endophytic bacterial fraction of Murraya koenigii (L.) Spreng. in rats | |
| EP2879647B1 (en) | Skin care | |
| Abubakar et al. | ANTIFUNGAL EFFECTS OF TAPINANTHUS GLOBIFERUS GROWING ON VITEX DONIANA AGAINST SOME FUNGAL ISOLATES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120229 Termination date: 20140601 |